Objectives: Several trials have documented the favorable safety profile, and promising clinical results of pressurized intraperitoneal aerosol chemotherapy (PIPAC) directed treatment in different types of peritoneal malignancies. However, until the results of randomized trials are available, the quality of documentation and acceptance by the users may be improved through a worldwide registry. The International Society for the Study of Pleura and Peritoneum (www.ISSPP.org) facilitated this process by creating a dedicated focus group and providing the funding needed for the creation and implementation of an international database. This article describes the design and the journey of establishing this international database and the first, preliminary results from the ISSPP PIPAC online database.
Methods: In 2019 the ISSPP PIPAC Registry Group started to create a database with a minimal dataset relevant to many diseases and applicable in different framework conditions. The task was divided into three phases including design, testing, implementation, protocol, handbook, legal requirements, as well as registry rules and bylaws for the registry group.
Results: The ISSPP PIPAC online database has six key elements (patient, consent, treatment, complications, response evaluation and follow-up). Following design, testing and implementation the database was successfully launched in June 2020. Ten institutions reported on 459 PIPAC procedures in 181 patients during the first 6 months, and the recorded data were comparable to the present literature.
Conclusions: A new international multicenter PIPAC database has been developed, tested and implemented under the auspices of ISSPP. The database is accessible through the ISSPP website (www.ISSPP.org), and PIPAC institutions worldwide are highly encouraged to participate.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8482445 | PMC |
| http://dx.doi.org/10.1515/pp-2021-0108 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Second annual report from the ISSPP PIPAC database.
Pleura Peritoneum
December 2023
Department of Surgery, Odense University Hospital, Odense, Denmark.
Objectives: To monitor the results of PIPAC directed therapy based on data from the International Society for the Study of the Pleura and Peritoneum (ISSPP) PIPAC database.
Methods: Analysis of data from patients entered between June 15th, 2020, and February 28th, 2023.
Results: Twelve centers reported 2,456 PIPAC procedures in 809 patients (median 2, range 1-18) with peritoneal metastasis (PM) from different primary tumors.
The role of cytology in patients undergoing pressurized intraperitoneal aerosol chemotherapy (PIPAC) treatment for peritoneal carcinomatosis.
Pleura Peritoneum
June 2023
Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Lausanne, Switzerland.
Article Synopsis
- The study focused on evaluating the role of cytology in patients with peritoneal metastases who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC) between 2015 and 2020.
- Out of 75 patients analyzed, 59% had positive cytology results at their first PIPAC, with differences in symptoms and ascites volume noted between those with positive and negative results.
- Overall survival was better for patients adhering to the treatment protocol (30.9 months) compared to those who had fewer than 3 PIPAC treatments (12.9 months), but cytology status had little impact on treatment decisions.
Nab-PIPAC: a phase IB study protocol of intraperitoneal cisplatin and nab-paclitaxel administered by pressurised intraperitoneal aerosol chemotherapy (PIPAC) in the treatment of advanced malignancies confined to the peritoneal cavity.
BMJ Open
January 2023
Département de chirurgie, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.
Introduction: Intraperitoneal dissemination is a major problem resulting in very poor prognosis and a rapid marked deterioration in the quality of life of patients. Pressurised intraperitoneal aerosol chemotherapy (PIPAC) is an emergent laparoscopic procedure aiming to maximise local efficacy and to reduce systemic side effects.
Methods And Analysis: Nab-PIPAC, a bicentre open-label phase IB, aims to evaluate safety of nab-paclitaxel and cisplatin association using in patients with peritoneal carcinomatosis (PC) of gastric, pancreatic or ovarian origin as ≥1 prior line of systemic therapy.
Assessment of Treatment Response after Pressurized Intra-Peritoneal Aerosol Chemotherapy (PIPAC) for Appendiceal Peritoneal Metastases.
Cancers (Basel)
October 2022
Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland.
Background The aim of this study was to analyse survival and surrogates for oncological response after PIPAC for appendiceal tumours. Methods This retrospective cohort study included consecutive patients with appendiceal peritoneal metastases (PM) treated in experienced PIPAC centers. Primary outcome measure was overall survival (OS) from the date of diagnosis of PM and from the start of PIPAC.
View Article and Find Full Text PDFSelection Criteria for Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Treatment in Patients with Peritoneal Metastases.
Cancers (Basel)
May 2022
Department of Visceral Surgery, Faculty of Biology and Medicine UNIL, Lausanne University Hospital (CHUV), Rue du Bugnon 46, 1011 Lausanne, Switzerland.
Article Synopsis
- The study investigates predictors that influence the completion of PIPAC treatment, which consists of three procedures, and its correlation with improved survival rates.
- It analyzes data from 183 patients undergoing PIPAC across three expert centers, revealing that 52% completed the full treatment protocol, with disease progression and bowel obstruction as main reasons for discontinuation.
- Key findings indicate that patients with less ascites and no history of bowel obstruction are more likely to complete treatment, and combining PIPAC with systemic chemotherapy enhances survival rates significantly.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!